BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.
- FY26 revenue surged 156% to $74.98 million
- Adjusted EBITDA soared 190% to $19 million
- Secured $50 million pharmaceutical supply deal with ADREXpharma Germany
- Expanded into Costa Rica's medicinal cannabis market
- Commissioning GMP manufacturing facility in Scotland
Record Financial Performance Caps Transformative FY26
BLS Pharmaceuticals Limited (ASX:BLS) delivered a standout FY26, reporting record quarterly revenue of $22.5 million, 5% higher than the previous quarter, and full-year revenue of $74.98 million, smashing prior year figures by 156% and landing at the top end of the company’s $65-75 million guidance. Adjusted EBITDA also hit a new high of $19 million, up 190% year-on-year, reflecting a business scaling its manufacturing and commercial operations effectively.
Cash flow dynamics reinforced the company’s operational strength, with positive operating cash flow of $6.3 million in the June quarter, the best quarterly result to date. Cash receipts remained robust at $20.7 million, and the cash balance rose to $13.3 million from $8.5 million three months prior, underpinning BLS’s growing financial resilience.
Major International Supply Agreements Drive Expansion
Central to BLS’s growth story was a landmark two-year pharmaceutical supply agreement with Germany’s ADREXpharma GmbH, valued at approximately $50 million, with a $25 million minimum commitment in the first year. This deal grants ADREXpharma exclusive rights to distribute BLS’s Dr Watson® medicinal cannabis products in Germany, Europe’s largest regulated medicinal cannabis market, positioning BLS for recurring revenues on the continent.
Simultaneously, BLS marked its entry into Latin America with the first international supply of medicinal cannabis flower to Costa Rica through an expanded agreement with Remidose LATAM SRL. This initial sale, valued at over $500,000, signals BLS’s strategic push into emerging regulated markets.
Manufacturing Capacity and Product Innovation
BLS is advancing its manufacturing footprint with the ongoing commissioning of a GMP pharmaceutical manufacturing facility in Scotland, on track for completion by September 2026. This facility will bolster production capacity and enable direct pharmaceutical supply into the UK market, complementing BLS’s operations across Australia, Europe, and Latin America.
The company also inked a manufacturing agreement with Aurora Cannabis Inc., supplying GMP-certified medicinal cannabis oils and vape products across Australia, the UK, and Germany. Initial sales volumes, over 5,000 sublingual oil units and 20,000 vape products, underscore BLS’s credibility as a pharmaceutical manufacturing partner to global players.
On the innovation front, BLS progressed commercialisation of its GMP-manufactured psilocybin capsules (BLSPSIL25) for investigational use in treatment-resistant depression and other mental health conditions. Initial sales support approximately 60 patients over 12 months, positioning BLS among the few Australian manufacturers with capabilities in psychedelic medicines.
Corporate Evolution and Governance Strengthening
Reflecting its evolution from Bioxyne Limited, the company completed its rebrand to BLS Pharmaceuticals Limited, with shares trading under the new ticker BLS since 7 July 2026. This name change aligns with its international pharmaceutical manufacturing focus and growth ambitions.
Governance was bolstered by the appointment of Edward Myer as an independent Non-Executive Director and Chair of the Audit and Finance Committee, bringing seasoned expertise in corporate finance and investment markets. Additionally, a 10-for-1 share consolidation was executed to support the company’s corporate transition.
Capital expenditure for the quarter was $2.6 million, primarily invested in the Scotland facility, funded alongside grants and loans, maintaining a strong balance sheet to support ongoing expansion.
FY27 Outlook Focused on International Growth and Manufacturing Scale
BLS enters FY27 with strong momentum, an expanded international platform, and a fortified balance sheet. The company plans to ramp up the ADREXpharma agreement in Germany, grow its European and Latin American footprints, increase pharmaceutical manufacturing activities, and complete commissioning of its Scotland facility. Audited FY26 results and FY27 guidance are expected around 26 August 2026, which will provide further clarity on the company’s trajectory.
Bottom Line?
BLS Pharmaceuticals has set a high bar with FY26 results and international contracts, but delivering on its Scotland facility and scaling new markets will test its growth thesis in FY27.
Questions in the middle?
- How quickly will BLS ramp up production and revenues from its Scotland GMP facility?
- Can the ADREXpharma partnership in Germany translate into sustained, recurring cash flows?
- What is the commercial potential and regulatory outlook for BLS’s psilocybin capsules beyond initial Australian sales?